CompanyLLYNYSEIndianapolis, IN

Eli Lilly

Eli Lilly develops medicines across multiple modalities including biologics and genetic medicine, with programs in diabetes, obesity, Alzheimer's disease, immune disorders, and oncology.

Stories only

SEC EDGAR ClinicalTrials.gov lilly.com

424B5Oct 1Latest SEC filing

Oct 1Latest story

October 2026

Foghorn and Lilly halt FHD-909 program, company cuts 40% of workforce

Oct 1PartnershipEli Lilly Foghorn Therapeutics Inc.

September 2026

Lilly posts Lyumjev safety results in India; registers new Alzheimer's Phase 1 study

Sep 29Weekly roundup, 5 itemsbaricitinib Cipla

FDA approves efficacy supplement for Eli Lilly's Olumiant (baricitinib)

Sep 25Regulatory decisionbaricitinib Eli Lilly

Loxo posts Phase 3 pirtobrutinib results; five more Lilly-linked trials update

Sep 25Weekly roundup, 6 itemsabemaciclib brenipatide

FDA approves Eli Lilly's Onswik, a new insulin efsitora alfa-gobe injection

Sep 23Regulatory decisionEli Lilly

FDA approves new efficacy supplement for Eli Lilly's Verzenio

Sep 18Regulatory decisionabemaciclib Eli Lilly

FDA approves supplemental application for Eli Lilly's Inluriyo

Sep 18Regulatory decisionEli Lilly imlunestrant

Lilly's orforglipron posts Phase 3 diabetes results; six new trials registered

Sep 18Weekly roundup, 7 itemsEli Lilly orforglipron

Lilly registers three new early trials: olomorasib in colorectal cancer, two obesity studies

Sep 11Weekly roundup, 3 itemsEli Lilly eloralintide

Lilly posts Phase 3 orforglipron results; two more programs report terminated-trial data

Sep 4Weekly roundup, 7 itemsEli Lilly lasmiditan

August 2026

FDA approves two efficacy supplements for Eli Lilly's Mounjaro

Aug 27Regulatory decisionEli Lilly tirzepatide

Lilly registers four new trials: Alzheimer's, cardiovascular, obesity, Crohn's programs

Aug 27Weekly roundup, 5 itemsclazakizumab Eli Lilly

FDA approves efficacy supplement for Lilly's Zepbound (tirzepatide)

Aug 26Regulatory decisionEli Lilly tirzepatide

Lilly registers Phase 3 depression trial; posts results for two psoriasis and oncology studies

Aug 20Weekly roundup, 5 itemsabemaciclib brenipatide

Lilly posts orforglipron Phase 3 results; adds new early-phase studies

Aug 14Weekly roundup, 6 itemsbaricitinib brenipatide

Absci reports Q2 2026 results, positive ABS-201 Phase 1 data, $100M raise with Lilly

Aug 11Quarterly updateAbsci Corp Eli Lilly

Amphastar hits BAQSIMI sales milestone, triggering $100 million payment to Lilly

Aug 6Quarterly updateAmphastar Pharmaceuticals, Inc.Eli Lilly

Foghorn reports Q2 2026 results, FHD-909 trial on track with Lilly

Aug 6Quarterly updateEli Lilly Foghorn Therapeutics Inc.

Lilly raises 2026 revenue guidance to $85-87 billion on Mounjaro, Zepbound growth

Aug 5Quarterly updateEli Lilly tirzepatide

Lilly wins two label supplements: orforglipron tablet and teriparatide solution

Aug 4Weekly roundup, 2 itemsEli Lilly orforglipron

Pipeline by stage

Phase 3 primary completions, next 6 months

Oct 2026baricitinibsystemic juvenile idiopathic arthritis · NCT04088396

Oct 2026retatrutidetype 2 diabetes · NCT06297603

Nov 2026tirzepatideobesity · NCT06662383

Feb 2027orforglipronobesity · NCT06672549

Details

Headquarters: Indianapolis, IN
Incorporated: Indiana
Industry: Pharmaceutical Preparations
Formerly: LILLY ELI & CO (to 2019); LILLY ELI & CO ET AL (to 1994)
Also known as: Dermira, ELI LILLY & Co, ImClone Systems, Lilly, and 6 more
LLY, Loxo Oncology, Morphic Therapeutic, Point Biopharma, Prevail Therapeutics, Versanis Bio

How the company describes itself

Eli Lilly develops medicines across multiple modalities including biologics and genetic medicine, with programs in diabetes, obesity, Alzheimer's disease, immune disorders, and oncology. source